Factors associated with common and atypical chromosome abnormalities after positive combined first-trimester screening in Chinese women: a retrospective cohort study

Annisa Mak1, Helena Lee1, C. F. Poon1, S. L. Kwok1, Teresa Ma1, K. Y. K. Chan2, Anita Kan2, Mary Tang3 and K. Y. Leung1*

Abstract

Background: When cell-free DNA (cfDNA) testing is used as a secondary screening tool following combined first-trimester screening (cFTS), cFTS is used to estimate the prior risk for chromosome abnormalities. This study aimed to assess the factors that are associated with common and atypical abnormalities following cFTS, including cFTS risk, advanced maternal age, increased nuchal translucency (NT) ≥3.5 mm, and abnormal levels of serum markers.

Methods: We reviewed a historical cohort of 1855 Chinese women carrying singleton pregnancies with a positive cFTS [at a threshold of 1:250 for trisomy (T) 21 or 1:180 for T18] in one public hospital over a five-year period. All chromosome abnormalities were confirmed by invasive prenatal diagnosis (IPD) with karyotyping, with or without array comparative genomic hybridization. Using multivariable binary logistic regression analysis, we determined the parameters that were associated with common and atypical abnormalities.

Results: Overall, the prevalence of common and atypical abnormalities was 6.2 and 1.2%, respectively, and the prevalence increased with the risk of T21 by cFTS. In pregnancies with a risk of T21 > 1 in 100, a high risk of both T21 and T18, an increased NT, or a pregnancy-associated plasma A (PAPP-A) level < 0.2 multiple of medians (MoM), the prevalence of common abnormalities was 12.2, 64.7, 25.5 and 33.8%, respectively, while that of atypical abnormalities was 1.6, 3.9, 4.2, and 7.4%, respectively. In the multivariable binary logistic regression analysis, out of these four factors, only two (increased NT and PAPP_A < 0.2 MoM) were significant predictors of common and atypical abnormalities, respectively. Of all positive cFTS pregnancies, 50.4% did not have any of these four factors, and the prevalence of common and atypical abnormalities was 1.1 and 0.6%, respectively. There were three atypical abnormalities, all of which were mosaicism, and they were detected among women with IPD alone. The ages of these women were ≥35 years. All three pregnancies were continued after proper counseling. After giving birth, only one child had mild abnormalities, while the other two were phenotypically normal.

Conclusions: Our study identified factors associated with common and atypical abnormalities after cFTS. These factors can be used to estimate the prior risk for these abnormalities to help with post-cFTS counseling in terms of choosing between cfDNA testing and IPD.

Keywords: Cell-free DNA screening, Non-invasive prenatal testing, Risk of atypical aneuploidies, Detection rate, Aneuploidy screening, Down syndrome

* Correspondence: Leungky1@ha.org.hk
1Department of Obstetrics and Gynaecology, Queen Elizabeth Hospital, 30 Gascoigne Road, Hong Kong, SAR, China
Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
A recent meta-analysis showed that non-invasive prenatal testing (NIPT) using cell-free DNA (cfDNA) in singleton pregnancies could detect > 99% of fetuses with trisomy 21 at a false positive rate (FPR) of 0.04% [1]. Short of offering women of any background risk of cfDNA testing as a primary screening tool [2], which is relatively expensive, universal combined first trimester screening (cFTS) is still an acceptable method of prenatal screening for trisomy 21 [3–5] because it can achieve a sensitivity of approximately 93% [6] and allows for the opportunity of an early detection of fetal structural abnormalities during nuchal translucency (NT) scanning.

Following a positive cFTS, cfDNA testing can be used as a secondary screening tool [3–5] because cfDNA testing can detect >99% of fetuses with trisomy 21, 98% of those with trisomy 18 and 99% of those with trisomy 13 at a combined FPR of 0.13%. It seems that cfDNA testing can also detect >95% of fetuses with sex chromosome aneuploidies (SCA) at an FPR of <1% according to small scale studies [1]. The use of cfDNA testing was accompanied by a significant decline in the rate of invasive prenatal diagnosis (IPD) following positive cFTS results [7–10] and a concomitant decrease in the potential risk of procedure-related fetal losses, albeit small (0.11–0.22%) according to a recent meta-analysis [11]. However, approximately 17–50% of abnormal chromosomes, including clinically relevant atypical abnormal karyotypes, may not be detected by targeted cfDNA testing focusing on common aneuploidies compared to IPD with chromosome microarray (CMA), which can enable the detection of submicroscopic duplications and deletions [12–14].

While cfDNA testing is used as a secondary screening tool, it is desirable to include a protocol in which women with very high risk are offered IPD and those with intermediate risk are offered cfDNA testing [4]. It is well known that IPD should be offered to women with pregnancies with an increased fetal nuchal translucency (NT) thickness (≥3.5 mm) or an ultrasound-detected abnormality because cfDNA testing may miss atypical aneuploidies at a rate of up to 8% [15]. In addition, recent studies on Danish and Australian populations suggest that the worry of missing atypical abnormalities (other than trisomies 13, 18, and 21 or SCA) can be reduced by offering IPD to pregnancies with a high trisomy 21 risk (>1 in 100) or a low pregnancy associated plasma protein-A (PAPP-A) level (<0.2 MoM) [12, 16].

The main objectives of our present study are to determine which factors, among cFTS risk, advanced maternal age, increased nuchal translucency (NT) ≥3.5 mm, and abnormal levels of serum markers, are associated with common and atypical abnormalities. If an individual’s risk of common and atypical abnormalities can be estimated by considering various parameters of cFTS, this information would be useful for counseling before and after cfDNA testing.

Methods
A retrospective cohort study was conducted on all women who had a singleton pregnancy and a prenatal screening for Down syndrome at Queen Elizabeth Hospital (QEH) in Hong Kong between August 2011 and July 2016. QEH is a public hospital with approximately 6000 deliveries a year, and the majority of the pregnant women are Chinese. This study was approved by the Research Ethics Committee of Kowloon Central/Kowloon East Cluster in Hong Kong, and patients consents were not required because this was a retrospective study. Furthermore, all the participants were anonymous.

Universal cFTS, involving an assessment of the NT, free β-human chorionic gonadotropin (β-hCG) and PAPP-A, was offered between 11 and 13 weeks and 6 days. The gestational age was determined by an ultrasonographic measurement of the crown rump length shortly after the first antenatal visit.

Women with a screening result for trisomy 21 of 1 in 250 or higher or with a screening result for trisomy 18 of 1 in 180 or higher were reported as ‘high risk’. These women were counseled by the maternal fetal medicine team of QEH on different options, including chorionic villus sampling (CVS), amniocentesis, cfDNA testing or no further testing. Women with a fetal NT ≥3.5 mm or with structural abnormalities were advised to undergo IPD rather than cfDNA testing, given that the latter may miss atypical aneuploidies at a rate of 8% [15]. All women were followed up for a mid-trimester anomaly scan and further counseling, post IPD or cfDNA testing. For those women who underwent cfDNA testing, IPD was offered for a positive cfDNA result, an ultrasound-detected fetal abnormality or a maternal concern.

Karyotype analyses of all the prenatal samples were performed by the Prenatal Diagnosis Laboratory of Tsan Yuk Hospital and Prenatal Genetic Diagnosis Centre at Prince of Wales Hospital, both of which are public prenatal diagnostic laboratories in Hong Kong. The analyses included quantitative fluorescent polymerase chain reaction for rapid aneuploidy detection and G-banded chromosome analyses. Array comparative genomic hybridization (aCGH) or fluorescence in situ hybridization (FISH) was performed for an ultrasound abnormality or for the characterization of a chromosome abnormality. NimbleGen manufactured CGX-135 k oligonucleotide array (Roche Diagnostics GmbH, Germany) was used for the samples analyzed in TYH before April 2014, and, thereafter, Agilent manufactured CGX 60 k oligonucleotide array (Perkin Elmer, USA) was used. Fetal DNA Chip (manufactured by Agilent) was used for the samples processed in PWH.
Commercial cfDNA testing was based on massively parallel sequencing with ‘shotgun’ counting of all cfDNA sequences or ‘targeted’ counting of specific DNA sequences or single nucleotide polymorphisms. The majority of the cfDNA testing were performed in three laboratories. All cfDNA reports included the risks for trisomies 21, 18, and 13 and, recently, the risks of SCA, selected microdeletions or duplications and aneuploidies involving other chromosomes.

cFTS and IPD were publicly funded, while the cfDNA testing and aCGH were self-financed (around $700 USD per test). Pregnancy outcomes were traced by reviewing hospital records or by phone contact for women who delivered outside of this hospital. Chromosomal analyses were performed after birth if it was clinically indicated, such as for the finding of congenital anomalies. We defined balanced translocation as ‘normal’ after the exclusion of microdeletions or duplications by aCGH and counseled women on their reproductive risk in the future. The women were also referred to clinical geneticists for family counseling or testing.

Statistical analysis
With the use of descriptive statistics, we determined the prevalence of common abnormalities (trisomies 13, 18 and 21 or SCA) and atypical abnormalities (including mosaicism or other abnormalities but excluding balanced translocations). Using the chi-square test, we assessed the prevalence of common and atypical abnormalities by using various known factors, including a maternal age ≥45, an NT thickness ≥3.5 mm, a risk of trisomy 21 > 1 in 100, a fβ-hCG < 0.2 or ≥5.0 multiple of medians (MoM), and a PAPP-A < 0.2 MoM [11]. We then included those significant factors and used a separate multivariable binary logistic regression analysis for the predictions of common and atypical abnormalities. In pregnancies without any of the significant factors, the prevalence of common and atypical abnormalities was compared between women receiving IPD alone and those receiving cfDNA testing.

To assess the extent of missed atypical abnormalities while some women chose cfDNA testing instead of IPD during the study period, we compared the prevalence of chromosome abnormalities between the one-year period before and the five-year period after the introduction of cfDNA testing. The statistical package software SPSS 21.0 (IBM, SPSS, Statistics for Windows, Version 21.0; IBM, Armonk, N.Y., U.S.A.) was used for all analyses.

Results
During the study period, 33,104 (97.5%) of the 33,952 pregnant women underwent routine Down syndrome screening, 28.9% of whom were aged 35 years or older. There were 2201 (6.7%) positive-screen pregnancies. After excluding 136 multiple pregnancies and 210 second trimester screenings, we studied the remaining 1855 women who had a positive cFTS, 95.8% of whom were Chinese, 752 of whom underwent a cfDNA testing, 986 of whom had IPD alone, and 117 of whom had no further testing at our hospital or at other places (Table 1). The prevalence of common chromosomal abnormalities was 6.2% (115/1855) and that of atypical abnormalities was 1.2% (22/1855) in the positive cFTS pregnancies (Table 1). The screening results of these 22 patients with atypical abnormalities are detailed in Table 2.

Table 1 Prevalence of chromosomal abnormalities after cell-free DNA (cfDNA) testing, invasive prenatal diagnosis (IPD) alone, and birth in singleton pregnancies following positive conventional screening results; n (%)  
|                        | cfDNA testing n = 752 | IPD alone n = 986 | No further test n = 117 | Total   |
|------------------------|-----------------------|------------------|------------------------|---------|
| Abnormal results       | 752                   | 0                | 752                    | 752     |
| IPD or karyotyping after birth⁴ | 34 (4.5%)⁴           | 986 (100.0%)     | 7 (6.0%)⁶              | 148     |
| Chromosome abnormalities| 21 (2.8%)             | 120 (12.2%)      | 7 (6.0%)               | 148     |
| Trisomy 21             | 14 (1.9%)             | 59 (6.0%)        | 2 (1.7%)               | 75      |
| Trisomy 18 or 13       | 3 (0.4%)              | 22 (2.2%)        | 4 (3.4%)               | 29      |
| Total                  | 148                   | 148              | 148                    | 444     |
| Other atypical abnormality  | 1 (0.1%)              | 10 (1.0%)        | 1 (0.9%)⁶              | 12      |
| Balanced translocation  | 0 (0%)                | 10 (1.0%)        | 0 (0%)                 | 10      |
| Unknown⁵               | 1 (0.1%)              | 0 (0%)           | 1 (0.1%)               | 2       |

⁴Of 34 IPD, 24 were performed for abnormal cfDNA testing and 10 for anxiety, despite a negative cfDNA testing and normal scan findings.
⁵Pregnancy was terminated at another hospital.
⁶Karyotyping (a) after birth in the group of women who declined further testing because they would keep their pregnancies anyway or worried about the IPD-related risk of miscarriage or (b) after miscarriage.
⁷Karyotyping of a placental sample after spontaneous miscarriage showed 47,XX+mar
Factors affecting the prevalence of common and atypical abnormalities

In general, the prevalence of common and atypical abnormalities increased with an increased risk of trisomy 21 by cFTS ($p < 0.001$), and it increased from 1.6 and 0.9% to 41.8 and 3.6%, respectively, when the cFTS risk was between 1 in 101 and 1 in 250 and when the cFTS risk was $\geq$ 1 in 10, respectively (Fig. 1).

The prevalence of common or atypical abnormalities in pregnancies with a risk of trisomy 21 $> 1$ in 100, a high risk of both trisomy 21 and trisomy 18, an NT $\geq$ 3.5 mm or a low PAPP-A level was significantly higher than those without a risk of these factors (Table 3). When none of these four risk factors were present, the prevalence of common and atypical abnormalities was 1.1 and 0.6%, respectively (Table 4); when one or more of these four risk factors were present, the corresponding prevalence was 11.5 and 1.7%, respectively (Table 4). In multivariable binary logistic regression analysis, all four of these risk factors were significant predictors of common abnormalities, while only a low PAPP_A and an NT $\geq$3.5 mm were significant predictors of atypical abnormalities, with adjusted ORs of 4.74 and 6.43, respectively (Table 5).

Of the total 1855 positive cFTS pregnancies, 935 (50.4%) did not have any of these four risk factors, and there were no significant differences in the prevalence of common or atypical or common abnormalities between women receiving cfDNA testing and those receiving IPD alone (1.1% vs. 1.0%, $p = 0.873$, 0% vs. 0.6%, $p = 0.251$). There were three atypical abnormalities, all of which were detected among the women who received IPD alone. The ages of these women were $\geq$ 35 years. These three chromosome abnormalities were mosaicism, including mos 47,XY,+r(18)dn[18]/46,XY[12], mos 47,XX,+r(18)dn[18]/46,XY[12], and mos 47,XX,+r(18)dn[18]/46,XY[12]. All three pregnancies continued after proper counseling by a maternal fetal medicine team. The first patient had a pointed chin, mild malformed left ear and mild hearing loss, while the other two patients were phenotypically normal after birth. A repeated chromosomal analysis on the peripheral blood in these two patients showed normal results.

### Discussion

This study showed that the prevalence of common abnormalities increased with an increased cFTS risk, from 1.6% in women with T21 risk between 1 in 101 and 1 in 170. The table below shows the combined first trimester screening results for these patients.

#### Table 2 Twenty-two patients with atypical chromosome abnormalities and their combined first trimester screening results

| Chromosome abnormalities | T21 risk (1:x) | T18 risk (1:x) | PAPP-A MoM | FB-hCG MoM | NT (mm) | NT MoM |
|--------------------------|----------------|----------------|-----------|-----------|---------|--------|
| 1                        | 10             | 970            | 0.34      | 0.78      | 12.60   | 7.15   |
| 2                        | 240            | 5900           | 1.64      | 0.88      | 6.40    | 4.12   |
| 3                        | 2              | 770            | 1.21      | 2.77      | 5.50    | 2.88   |
| 4                        | 120            | 180            | 0.63      | 0.24      | 5.50    | 3.89   |
| 5                        | 6              | 2700           | 1.25      | 1.22      | 4.90    | 2.97   |
| 6                        | 140            | 27000          | 1.06      | 1.76      | 2.50    | 1.40   |
| 7                        | 230            | 100,000        | 1.63      | 4.07      | 2.50    | 1.39   |
| 8                        | 40             | 92,000         | 0.21      | 2.05      | 2.20    | 1.22   |
| 9                        | 90             | 10,000         | 0.21      | 0.96      | 1.90    | 1.21   |
| 10                       | 170            | 100,000        | 0.19      | 1.52      | 1.60    | 1.08   |
| 11                       | 11             | 2800           | 0.09      | 1.67      | 1.40    | 0.91   |
| 12                       | 210            | 100,000        | 0.45      | 1.47      | 2.10    | 1.20   |
| 13                       | 2              | 320            | 0.11      | 1.74      | 4.70    | 3.13   |
| 14                       | 3              | 130            | 1.00      | 0.68      | 4.60    | 2.87   |
| 15                       | 220            | 10,000         | 0.43      | 0.92      | 2.10    | 1.14   |
| 16                       | 14             | 16,000         | 0.18      | 1.45      | 1.90    | 1.20   |
| 17                       | 30             | 100,000        | 0.25      | 3.46      | 1.70    | 1.01   |
| 18                       | 110            | 100,000        | 0.33      | 2.18      | 1.40    | 0.82   |
| 19                       | 6              | 51,000         | 0.12      | 2.76      | 1.40    | 0.90   |
| 20                       | 20             | 6000           | 1.14      | 1.03      | 10.30   | 5.78   |
| 21                       | 11             | 16,000         | 1.45      | 2.98      | 4.10    | 2.77   |
| 22                       | 180            | 100,000        | 0.35      | 1.88      | 1.80    | 1.06   |

Risk of trisomy 21 (T21), risk of trisomy 18 (T18), nuchal translucency (NT), pregnancy associated plasma protein A (PAPP-A), free $\beta$-human chorionic gonadotropin (f$\beta$-hCG), and multiple of medians (MoM)
Table 3  Chromosome abnormalities by maternal age, risk of trisomy 21 (T21), nuchal translucency (NT), pregnancy associated plasma protein A (PAPP-A) and free β-human chorionic gonadotropin (fβ-hCG)

|                        | Total pregnancies | Total abnormalities | T21,18 or 13 or SCA | Atypical abnormalities | p       |
|------------------------|-------------------|---------------------|----------------------|------------------------|---------|
| High risk for T21 ≥ 1 in 250 | 1799              | 99                  | 79 (4.4%)            | 20 (1.1%)              | < 0.001*|
| High risk for 18 ≥ 1 in 180 | 5                 | 4                   | 3 (60.0%)            | 0 (0%)                 |         |
| High risk for T21 and 18 | 51                | 34                  | 33 (64.7%)           | 2 (3.9%)               |         |
| Risk of T21 > 1 in 100  | 793               | 111                 | 97 (12.2%)           | 13 (1.6%)              | < 0.001*|
| Risk of T21 < 1 in 100  | 1062              | 26                  | 18 (1.7%)            | 9 (0.8%)               |         |
| Age ≥ 45                | 20                | 2                   | 2 (10.0%)            | 0 (0%)                 | 0.899   |
| Age ≥ 35 < 45           | 1190              | 87                  | 74 (6.2%)            | 14 (1.2%)              |         |
| Age < 35                | 645               | 48                  | 39 (6.0%)            | 8 (1.2%)               |         |
| NT (mm) median (range)  | 1855              | 137                 | 3.8 (1.1–12.2)       | 2.4 (1.4–12.6)         |         |
| NT MoM                  | 1855              | 137                 | 2.26 (0.68–7.19)     | 1.31 (0.82–7.15)       |         |
| NT ≥ 3.5 mm             | 216               | 65                  | 55 (25.5%)           | 9 (4.2%)               | < 0.001*|
| NT < 3.5 mm             | 1639              | 72                  | 60 (3.7%)            | 13 (0.8%)              |         |
| PAPP-A MoM              | 1855              | 137                 | 0.32 (0.05–2.32)     | 0.39 (0.09–1.64)       |         |
| Low PAPP-A              | 68                | 27                  | 23 (33.8%)           | 5 (7.4%)               | < 0.001*|
| Normal PAPP-A           | 1787              | 110                 | 92 (5.1%)            | 17 (1.0%)              |         |
| fβ-hCG MOM              | 1855              | 137                 | 1.44 (0.03–9.75)     | 1.60 (0.24–4.07)       |         |
| Low or high fβ-hCG     | 98                | 7                   | 7 (7.1%)             | 0 (0%)                 | 0.503   |
| Normal fβ-hCG           | 1757              | 130                 | 108 (6.1%)           | 22 (1.3%)              |         |

**Fig. 1** The prevalence of common abnormalities (trisomies 21, 18, and 13 and sex chromosome aneuploidies) and atypical (or other) abnormalities by the risk of trisomy 21 after combined first trimester screening.
medians, and a high risk for both trisomy 21 and trisomy 18 pregnancy associated plasma protein A (PAPP-A) < 0.2 multiple of medians, and a high risk for both trisomy 21 and trisomy 18.

Table 4 Prevalence of common chromosome abnormalities [trisomies (T) 21, 18 and 13 and sex chromosome abnormalities] and atypical (or other) abnormalities in screen-positive pregnancies with or without any of the four risk factors, including a risk of T21 > 1 in 100, a nuchal translucency (NT) ≥ 3.5 mm, a low pregnancy associated plasma protein A (PAPP-A) < 0.2 multiple of medians, and a high risk for both trisomy 21 and trisomy 18.

| No risk factors | Common abnormalities | Atypical abnormalities |
|-----------------|----------------------|------------------------|
| 1.1%            | 0.6%                 |

| One or more of the risk factors | Common abnormalities | Atypical abnormalities |
|-------------------------------|----------------------|------------------------|
| 11.5%                        | 1.7%                 |

250 to 41.8% for women with risk ≥1 in 10. The prevalence of atypical abnormalities also increased with an increased cFTS risk in these women, from 0.9 to 3.6%, respectively. The prevalence of common abnormalities and that of atypical abnormalities was 1.1 and 0.6%, respectively, when none of these four risk factors (a risk of T21 > 1 in 100, a high risk of both T21 and T18, a PAPP-A < 0.2 MoM, and an increased NT) were present, and the prevalence was 11.5 and 1.7%, respectively, when one or more of these four risk factors were present. In the multivariable logistic regression analysis, all four of these risk factors and only the last two risk factors were significant predictors of common and atypical abnormalities, respectively.

These results are similar to the results of two large studies [12, 16]. In a study on the Danish population, the prevalence of atypical abnormalities increased in pregnancies with an increased fetal NT or cFTS risk, or those with a low PAPP-A [12]. The prevalence was 2.3, 1.6, and 4.2% in pregnancies with an NT in the >99th percentile, a cFTS risk≥ 1 in 100 and a low PAPP-A, respectively [12]. In a study on the Australian population, the prevalence of atypical abnormalities increased with an increased cFTS risk, and it was 4.6% in those pregnancies with a cFTS risk > 1 in 10 and 6.9% in pregnancies with a low PAPP-A [16].

Of all 22 pregnancies with atypical abnormalities, six, or 27.3%, did not have any of the abovementioned four factors, except for maternal age ≥35 in four of these six patients. These results are consistent with a previous study in which there were no such abnormal features in approximately 21% of pregnancies with atypical aneuploidies, except for a maternal age of 35 or above [13].

In contrast to previous studies [12, 16], we did not find that a greater maternal age and an abnormal level of β-hCG were significant risk factors for atypical abnormalities. This discrepancy may be due to the limitations of our present study, which include a small sample size, the exclusion of intermediate risk populations and a low percentage of samples tested with aCGH.

The present study was conducted at one large center over a five-year period in Chinese women. All except one abnormal cfDNA result were confirmed by IPD or after birth (Table 1). We used logistic regression analysis to assess the factors associated with common and atypical chromosome abnormalities. We did not present the sensitivity and specificity for each marker. The result of individual marker such as PAPP-A should be interpreted along with that of a cFTS. We do not have the full karyotype data on all pregnancies because some women underwent cfDNA testing instead of IPD. However, we did not find any newborns with significant chromosome abnormalities. Besides, there was no significant difference in the prevalence of atypical or common abnormalities between the one-year period before and the five-year period after the introduction of cfDNA testing (0.8% vs. 1.2%, p = 0.62; 5.8% vs. 6.2%, p = 0.8). One, or 4.5%, of the 22 atypical abnormalities was identified through an abnormal cfDNA testing result (Table 1). Recent studies have shown that cfDNA testing with advanced technologies can detect selected microdeletions or rare autosomal trisomies as well as common trisomies [17–21].

aCGH, which was self-financed, was performed in less than 10% of the IPD procedures, and the prevalence of atypical abnormalities in the present study was lower than that reported on routine CMA after high-risk cFTS (2.0–2.2%) [16, 22]. It is possible that a few atypical abnormalities in our cohort might have been missed. There is a need to increase the use of CMA, and further studies are required. In addition, cut-offs of cFTS vary among different countries. Variable and evolving platforms of cfDNA

Table 5 Prediction of common chromosome abnormalities [trisomies (T) 21, 18 and 13 and sex chromosome abnormalities] and atypical (or other) abnormalities by risk factors, including a risk of T21 > 1 in 100, a nuchal translucency (NT) ≥ 3.5 mm, a low pregnancy associated plasma protein A (PAPP-A) < 0.2 multiple of medians, and a high risk for both trisomy 21 and trisomy 18, after conventional screening

| Factors                        | Common abnormalities | Atypical abnormalities |
|-------------------------------|----------------------|------------------------|
|                               | Unadjusted OR (95% CI) | Adjusted OR (95% CI) | Unadjusted OR (95% CI) | Adjusted OR (95% CI) |
| High risk for both T21 and T18| 38.50 (20.80–71.25)* | 12.14 (6.01–24.33)* | 1.70 (0.22–12.87) | 0.17 (0.02–1.67) |
| Risk of T21 > 1 in 100        | 8.08 (4.84–13.49)*   | 5.51 (3.26–9.31)*    | 2.37 (0.99–5.67) | 1.44 (0.56–3.70) |
| NT ≥ 3.5 mm,                   | 8.99 (6.03–13.42)*   | 4.05 (2.56–6.41)*    | 6.58 (2.81–15.42)* | 6.43 (2.70–15.33)* |
| Low PAPP-A                    | 9.42 (5.46–16.23)*   | 4.49 (2.16–9.35)*    | 6.14 (2.02–18.67)* | 4.74 (1.49–15.01)* |

OR odds ratio, CI confidence interval.

*statistically significant (p < 0.05), unadjusted OR after univariate analysis, adjusted OR after multivariable binary logistic regression.
testing, offered by individual providers, may have a variable performance for SCA, mosaicism and other chromosome abnormalities [13, 23]. Of the 117 screen-positive women who declined further prenatal testing, seven had karyotyping of their newborns after birth of an abnormal phenotype (Table 1), and the remaining 110 did not have chromosome analysis because their babies were phenotypically normal. Among the screen-negative pregnancies, karyotyping was performed after birth only if abnormal phenotypes were found, and five babies with Down syndrome were diagnosed. All atypical abnormalities found were analyzed in the present study. Although some marker chromosomes and mosaic karyotypes are not accompanied by physiological problems in the affected children, prenatal prediction of their phenotype is difficult.

It is debatable how to best integrate cfDNA testing into current prenatal screening programs [24, 25]. A contingent approach of using cfDNA testing as a secondary screening tool following routine cFTS is a cost-effective approach [26, 27]. cFTS provides information on a priori risk for chromosome abnormalities [28] and can detect abnormalities other than trisomy 21 [29, 30]. At present, a cFTS report includes the risk of common trisomies but not that of SCA or atypical abnormalities. From the results of our present study, if none of these four risk factors (a risk of trisomy 21 > 1 in 100, a high risk of both trisomy 21 and trisomy 18, a low PAPP-A and an NT ≥ 3.5 mm) are present, which occurs in approximately half of cFTS-positive pregnancies, the prevalence of common and atypical abnormalities will be approximately 1.1% and 0.6% respectively, and the residual risk after a negative cfDNA testing will thus be small. If there is one or more of these risk factors, the prevalence of atypical abnormalities will range from 1.6 to 7.4% (Table 3), and the remaining 110 did not have chromosome analysis after birth of an abnormal phenotype. From the results of our present study, if none of these four risk factors (a risk of trisomy 21 > 1 in 100, a high risk of both trisomy 21 and trisomy 18, a low PAPP-A and an NT ≥ 3.5 mm) are present, which occurs in approximately half of cFTS-positive pregnancies, the prevalence of common and atypical abnormalities will be approximately 1.1% and 0.6% respectively, and the residual risk after a negative cfDNA testing will thus be small. If there is one or more of these risk factors, the prevalence of atypical abnormalities will range from 1.6 to 7.4% (Table 3), and IPD will be preferably offered as the first choice of treatment according to the current recommendations and evidence [12, 15, 16]. Because the prevalence of common abnormalities can be as high as 41.8% when the risk of trisomy 21 is > 1 in 10 by cFTS, there will also be a residual risk of missing common abnormalities after a negative cfDNA test if the fetal fraction and the precision of its measurement are low [27].

Using the abovementioned approach, we were able to detect approximately 72.7% (16/22) of atypical abnormalities in cFTS-positive pregnancies with 49.6% IPD. Offering IPD for an ultrasound-detected abnormality or an advanced maternal age ≥ 35 may help detect the remaining 27.3% [16]. More than half of the atypical abnormalities occurred in women with a cFTS below 1 in 300 and were found via ultrasound abnormalities [16]. Although approximately half of the prenatally detectable structural anomalies can be detected by a high-quality detailed scan at 12–13 weeks [31], some anomalies are only detectable in a mid-trimester scan. If CVS is performed in the first trimester for positive cFTS with one or more risk factors and if only karyotyping is performed, we suggest alerting the laboratory of the possibility of further testing by CMA, should anomalies be found subsequently. When deciding between cfDNA testing and IPD, patients use more than just the screening risk, and they may consider family values, finances and other issues. For some women who wish to maximize the detection of fetal atypical abnormalities, offering all high-risk cFTS pregnancies IPD with CMA is an option, but it comes with a procedure-related risk of miscarriage, albeit a small risk [22, 32]. For some women who wish to avoid an IPD, proper pre-test counseling before cfDNA testing should be provided to facilitate an informed choice [33]. Approximately one-fourth of these patients may not recognize the limited sensitivity of cfDNA testing, according to a previous local study [34]. Educating both healthcare professionals and patients is important [33].

**Conclusion**

Similar to studies on Caucasians [12, 15, 16], our study identified the factors associated with common and atypical fetal abnormalities after cFTS. The factors can be used to estimate the prior risk of these abnormalities. The information may help the maternal decision regarding cfDNA testing versus IPD following a positive cFTS.

**Abbreviations**

cCGH: Array comparative genomic hybridization; cfDNA: Cell-free DNA; cFTS: Combined first-trimester screening; CMA: Chromosome microarray; CVS: Chorionic villus sampling; β-hCG: Free β-human chorionic gonadotropin; IPD: Invasive prenatal diagnosis; NT: Nuchal translucency; PAPP-A: Pregnancy associated plasma protein-A; QEH: Queen Elizabeth Hospital; SCA: Sex chromosome aneuploidies; T: Trisomy

**Acknowledgements**

Not applicable.

**Funding**

No grants or external funding to report.

**Availability of data and materials**

The datasets of the atypical chromosome abnormalities used and/or analyzed during the current study are shown in Table 2. Other datasets are available from the corresponding author on reasonable request.

**Authors’ contributions**

AM, HL, TM and KY are obstetricians. CFP and SLK are midwives. KYKC is a scientist, AK and MT are obstetricians working in a prenatal diagnostic laboratory. AM, HL, TM, and KYL conceived and designed this study. AM contributed to the laboratory work, and contributed to the collection of clinical data. KYKC, AK and MT performed the laboratory work, and contributed to the collection of laboratory data, and critical evaluation of the manuscript. AM and KYKC drafted the manuscript and analyzed the data. All authors contributed significantly, read and approved the final manuscript.

**Ethics approval and consent to participate**

This study was approved by the Research Ethics Committee of Kowloon Central/Kowloon East Cluster, Hong Kong, and patient consent was not
required because this was a retrospective study. Furthermore, all the participants were anonymous.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 Department of Obstetrics and Gynaecology, Queen Elizabeth Hospital, 30 Gascogne Road, Hong Kong, SAR, China. 2 Department of Obstetrics and Gynaecology, Queen Mary Hospital, The University of Hong Kong, 102 Pokfulam Road, Hong Kong, SAR, China.

Received: 6 March 2018 Accepted: 28 January 2019
Published online: 04 February 2019

References
1. Gil MM, Accurti V, Santacruz B, Plana MN, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol. 2017;50:302–14.
2. Geigg AR, Slotho BM, Benkendorf JL, Monaghan KG, Bajaj K, Best RG, et al. Noninvasive prenatal screening for fetal aneuploidy, 2016: update a position statement of the American College of Medical Genetics and Genomics. Genet Med. 2016;18:1056–65.
3. Salomon LJ, Alfrieric Z, Audibert F, Kagan KO, Paladini D, Yeo G, et al. ISUOG clinical standards committee. ISUOG consensus statement on the impact of non-invasive prenatal testing (NIPT) on prenatal ultrasound practice. Ultrasound Obstet Gynecol. 2014;44:122–3.
4. Benn P, Borell A, Chiu RWK, Cuckle H, Doughoff L, Faas B, et al. Position statement from the chromosome abnormality screening committee on behalf of the Board of the International Society for prenatal diagnosis. Prenat Diagn. 2015;35:275–34.
5. Committee Opinion No. 640. Cell-free DNA screening for fetal aneuploidy. Obstet Gynecol. 2015;126:e31–7.
6. Baer RJ, Flessel MC, Jeffiffe-Pawlowski LL, Goldman S, Hudgins L, Hull AD, et al. Detection rates for aneuploidy by first-trimester and sequential screening. Obstet Gynecol. 2015;126:753–9.
7. Chetty S, Garabedian MJ, Norton ME. Uptake of noninvasive prenatal testing (NIPT) in women following positive aneuploidy screening. Prenat Diagn. 2013;33:542–6.
8. Larion S, Romany L, Mlynarczyk M, Abuhamad AZ, Warsof SL. Changes in prenatal testing trends after introduction of noninvasive prenatal testing. Obstet Gynecol. 2014;123:1303–10.
9. Poon CF, Tse WC, Kou KO, Leung KY. Uptake of noninvasive prenatal testing in Chinese women following positive Down syndrome screening. Fetal Diagn Ther. 2015;37:141–7.
10. Hui L, Hutchinson B, Poulton A, Halliday J. Population-based impact of noninvasive prenatal screening on screening and diagnostic testing for fetal aneuploidy. Genet Med. 2017;19:1338–45.
11. Wulf CB, Gerds TA, Rode L, Ekelund CK, Petersen OB, Tabor A. Danish fetal medicine study group. Risk of fetal loss associated with invasive testing following combined first-trimester screening for Down syndrome: a national cohort of 147,987 singleton pregnancies. Ultrasound Obstet Gynecol. 2016;47:38–44.
12. Petersen OB, Vogel I, Ekelund C, Hyett J, Tabor A. Danish fetal medicine study group; Danish clinical genetics study group. Potential diagnostic consequences of applying non-invasive prenatal testing: population-based study from a country with existing first-trimester screening. Ultrasound Obstet Gynecol. 2014;43:265–71.
13. Shani H, Goldwasser T, Neating J, Kugman S. Chromosomal abnormalities not currently detected by cell-free fetal DNA: a retrospective analysis at a single center. Am J Obstet Gynecol. 2016;214:729.e1–729.e11.
14. Norton ME, Baer RJ, Wapner RJ, Kupferman M, Jeffiffe-Pawlowski L, Curier RJ. Cell-free DNA vs sequential screening for the detection of fetal chromosomal abnormalities. Am J Obstet Gynecol. 2016;214:727.e1–6.
15. Benachi A, Letermeau A, Kleininger P, Senat MV, Gautier E, Favre R, et al. Collaborative SQuencage a haut deit eneuploidies (SEHDA) study group. Cell-free DNA analysis in maternal plasma in cases of fetal abnormalities detected on ultrasound examination. Obstet Gynecol. 2015;125:1330–7.
16. Lindquist A, Poulton A, Halliday J, Hui L. Prenatal diagnostic testing and atypical chromosome abnormalities following combined first-trimester screening: implications for contingent models of non-invasive prenatal testing. Ultrasound Obstet Gynecol. 2018;51:487–92.
17. Li R, Wan J, Zhang Y, Fu Y, Ou Y, Jing X, et al. Detection of fetal copy number variants by non-invasive prenatal testing for common aneuploidies. Ultrasound Obstet Gynecol. 2016;47:53–7.
18. Leftovitz RB, Tyman JA, Liu T, Wu Y, Mazloom AR, Almasi E, et al. Clinical validation of a noninvasive prenatal test for genomewide detection of fetal copy number variants. Am J Obstet Gynecol. 2016;215:227.e1–227.e16.
19. Liu H, Gao Y, Hu Z, Lin L, Yin X, Wang J, et al. Performance evaluation of NIPT in detection of chromosomal copy number variants using low-coverage whole-genome sequencing of plasma DNA. PLoS One. 2016;11:e015923.
20. Helgeson J, Wardrop J, Almasi E, Paxton WB, Saidfar JS, et al. Clinical outcome of subchromosomal events detected by whole-genome noninvasive prenatal testing. Prenat Diagn. 2015;35:999–1004.
21. Pettite MD, Halks-Miller M, Flowers N, Barbaciel C, Kinnings SL, Varek D, et al. Rare autosomal trisomies, revealed by maternal plasma DNA sequencing, suggest increased risk of feto-placental disease. Sci Transl Med. 2017. https://doi.org/10.1126/scitranslmed.aan1240.
22. Vogel I, Petersen OB, Christiansen R, Hyett J, Lou S, Vestergaard EM. Chromosomal microarray as a primary diagnostic genomic tool for pregnancies defined as being at increased risk within a population based combined first-trimester screening program. Ultrasound Obstet Gynecol. 2018;51:480–6.
23. Petersen AK, Cheung SW, Smith JL, Bi W, Ward PA, Peacock S, et al. Positive predictive value estimates for cell-free noninvasive prenatal screening from data of a large referral genetic diagnostic laboratory. Am J Obstet Gynecol. 2017;217:691.e1–6.
24. Borrell A, Stergiotou I. Cell-free DNA testing: inadequate implementation of an outstanding technique. Ultrasound Obstet Gynecol. 2015;45:508–11.
25. Oepkes P, Page-Christiaens GC, Bax CJ, Bekker MN, Bilardo CM, Bourn EM, et al. For the Dutch NIPT consortium, et al. Trial by Dutch laboratories for evaluation of non-invasive prenatal testing. Part I-clinical impact. Prenat Diagn. 2016;36:1083–90.
26. Song K, Musci TJ, Caughhey AB. Clinical utility and cost of non-invasive prenatal testing with cDNA analysis in high-risk women based on a US population. J Matern Fetal Neonatal Med. 2013;26:189–95.
27. Colosi E, Agramont V, Periti E. First trimester contingent screening for trisomies 21, 18, and 13. Prenat Diagn. 2015;35:612–18.
28. Breathnach FM, Malone FD, Lambert-Messerlian G, Cuckle HS, Porter TF, Nyberg DA, et al. First and second trimester evaluation of risk (FASTER) research consortium. First- and second-trimester screening: detection of aneuploidies other than Down syndrome. Obstet Gynecol. 2007;110:651–7.
29. Breathnach FM, Malone FD, Lambert-Messerlian G, Cuckle HS, Porter TF, Nyberg DA, et al. First and second trimester evaluation of risk (FASTER) research consortium. First- and second-trimester screening: implications for contingent models of non-invasive prenatal testing. Ultrasound Obstet Gynecol. 2015;45:40–54.
30. Faith D, Wright S, Nicolaides KH. An unified approach to risk assessment for fetal aneuploidies. Ultrasound Obstet Gynecol. 2015;45:40–54.
31. Breathnach FM, Malone FD, Lambert-Messerlian G, Cuckle HS, Porter TF, Nyberg DA, et al. First and second trimester evaluation of risk (FASTER) research consortium. First- and second-trimester screening: detection of aneuploidies other than Down syndrome. Obstet Gynecol. 2007;110:651–7.
32. Tørring N, Petersen OB, Becher N, Vogel I, Uldberg N. Danish fetal medicine study group; Danish clinical genetics study group. First trimester screening for other trisomies than trisomy 21, 18, and 13. Prenat Diagn. 2015;35:612–19.
33. Kenmoku MJ, Bakker M, Bard F, Fontanella F, Bakker MK, Fleuren-Rozenh A, et al. Yield of a 12–13 week scan for the early diagnosis of fetal congenital anomalies in the cell-free DNA era. Ultrasound Obstet Gynecol. 2018;51:463–9.
34. Evans M, Wapner RJ, Berkowitz RL. Noninvasive prenatal screening or advanced diagnostic testing: caveat emptor. Am J Obstet Gynecol. 2016;215:295–305.
35. Gaubitz SC, Luchansky-A, Buchanan A, Noritzi E, Bianchi DW. Recommended pre-test counseling points for noninvasive prenatal testing using cell-free DNA: a 2015 perspective. Prenat Diagn. 2015;35:968–71.
36. Koon KD, Poon CF, Tse WC, Mak SL, Leung KY. Knowledge and future preference of Chinese women in a major public hospital in Hong Kong after undergoing non-invasive prenatal testing for positive aneuploidy screening: a questionnaire survey. BMC Pregnancy Childbirth. 2015;15:199.